Navigation Links
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
Date:9/22/2008

n or more than 60 years of age). The prognostic value of various molecular markers will also be studied.

The trial is expected to start this fall and will be conducted at various sites in France.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Laromustine (Cloretazine(R) (VNP40101M)), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia (AML). The Company is also conducting clinical trials of laromustine (Cloretazine(R) (VNP40101M)) with cytarabine in elderly patients with AML, with temozolomide in patients with brain tumors, and with stem cell transplants in patients with advanced hematologic malignancies. A Phase III trial of laromustine (Cloretazine(R) (VNP40101M)) in combination with standard induction therapy in previously untreated AML and high-risk myelodysplastic syndrome (MDS) patients is expected to start this fall. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's web site at http://www.vionpharm.com.

About Institut Paoli-Calmettes

The Institut Paoli-Calmettes Cancer Center (IPC) is a private non-profit institution. Located in Marseille, IPC is a regional university hospital that is part of a network of 20 cancer treatment centers in France. Institut Paoli-Calmettes sets out to organize and prioritize the synergies between fundamental research, transfer laboratories, biotechnology companies and hospital departments. Employing the latest in innovation, Institut Paol
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 About Duchenne muscular ... disease, which generally affects the male population. It ... The disease is caused due to mutations in ... of production of dystrophin (a protein essential for ... of dystrophin weakens muscle function, causes loss of ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... is a malignant condition characterized by increased production of ... affects B-lymphocytes and then it can spread to other ... at later stages because of the slow buildup of ... the malignancy spreads to the spleen, liver, and lymph ...
Breaking Medicine Technology:Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 2Global Duchenne Muscular Dystrophy Drugs Market 2015-2019 3Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3
... Xlumena, Inc., a privately-held provider of innovative technology ... that it has received CE Mark approval for its ... system that enables exchange-free access, tract dilation and delivery ... NAVIX will join the AXIOS Stent and Delivery System ...
... The Chinese Biopharmaceutical Association-USA (CBA) successfully held its 16 ... US.   With the theme of ... the conference drew nearly 500 attendees with ... exhibited at the conference, including Chinese leading biotech parks, ...
Cached Medicine Technology:Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 2Chinese Biopharmaceutical Association Successfully Holds 16th Annual Conference 3
(Date:9/2/2015)... ... September 02, 2015 , ... Telehealth represents a growing trend among ... handle the telehealth services of more than 12 Blues plan clients. The September ... takes a look this growing trend, interviewing executives at Capital Blue Cross, whose telehealth ...
(Date:9/2/2015)... ... September 02, 2015 , ... In “Failure Lab: Weight Loss Surgery was ... August 25th, writer Akela Stanfield detailed her lifelong struggle with obesity that eventually led ... had always seen herself as someone who would lose weight through sheer self-control, the ...
(Date:9/2/2015)... ... September 02, 2015 , ... Splashtop Inc., the ... to its screen mirroring and extending product line -- Splashtop Wired XDisplay ... in local WIFI setting, the new Splashtop Wired XDisplay delivers enhanced performance and ...
(Date:9/2/2015)... ... September 02, 2015 , ... Good health and a good ... Shield of New Jersey (Horizon BCBSNJ) donated $11,000 to the New Jersey Golf Foundation ... foundation at the start of The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and ...
(Date:9/2/2015)... , ... September 02, 2015 , ... ... combining both naturopathic and allopathic medicine, opens its second location this week at ... features roughly 1000 square feet of lounge space for patients to relax while ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4
... ABT ),will present at the Citi Investment Research ... C. Freyman, executive vice president,finance and chief financial officer, ... Central time., A live audio webcast of the ... at http://www.abbottinvestor.com . An,archived edition of the presentation ...
... With the economy tight and,sales forces shrinking across ... maintain an effective sales force. Regardless, a company,s ... success going forward. That,success is predicated on establishing ... goals and managing groups in a way,that meets ...
... increase the risk of Alzheimers Disease by as much as ... issue of Obesity Reviews. , But its not just weight ... have an elevated risk of dementia, unlike people who are ... detailed review of 10 international studies published since 1995, covering ...
... staffing company to launch nationally-syndicated television ... ... Access,Nurses announced today a national campaign to change the image of nursing,in ... lives of nurses working on the front lines of modern,healthcare. The show, ...
... May 7 Emageon Inc. (Nasdaq:,EMAG), a leader in ... imaging facilities, will hold its,quarterly conference call to discuss ... at 10:00 AM Eastern Time. The company anticipates,that these ... the NASDAQ,stock market opens on May 12, 2008., ...
... May 7 AMDL, Inc. (Amex: ... in Shenzhen, Jiangxi,and Jilin, China, is a ... its subsidiary Jade Pharmaceutical Inc. (JPI),the Company ... of diagnostic, pharmaceutical, nutritional supplement, and,cosmetic products., ...
Cached Medicine News:Health News:Best Practice Database: Complimentary Excerpt of Three Sales Force Excellence Studies 2Health News:Obesity can increase dementia risk by up to 80 percent 2Health News:Nursing Shortage Spurs Campaign to Change the Image of Nursing in the Media 2Health News:Emageon Inc. to Host First Quarter 2008 Financial Results Conference Call May 12, 2008 2Health News:AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company 2Health News:AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: